Early intervention in multiple sclerosis: Better outcomes for patients and society?

Drugs

Volumn 63, Issue 15, 2003, Pages 1525-1533

  Flachenecker, Peter ^a   Rieckmann, Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; MITOXANTRONE; RALENOVA;

CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISABILITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOMODULATION; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT;

CLINICAL TRIALS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; INTERFERON TYPE I, RECOMBINANT; MULTIPLE SCLEROSIS; PEPTIDES; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0043124576     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363150-00001     Document Type: Review

References (52)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-31
2. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu Rev Med 2002; 53: 285-302
3. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-11
4. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis. A geographically based study: 1, clinical course and disability. Brain 1989; 112: 133-46
5. Goodin DS, Frohman EM, Garmany Jr GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-78
6. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52
7. Filippi M, Horsfield MA, Ader HJ, et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998; 43: 499-506
8. Rieckmann P, Toyka KV, Austrian-German-Swiss Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis. Eur Neurol 1999; 42: 121-7
9. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I, clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61
10. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1 a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94
11. Prisms Study Group. Randomised double-blind placebo-controlled study of interferon beta-1 a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504
12. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995; 45: 1268-76
13. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability: Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50: 701-8
14. Comi G, Filippi M, Wolinsky JS, et al. European/Canadian, multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001; 49: 290-7
15. Oger J, Freedman M. Consensus statement of the Canadian MS clinics network on the use of disease modifying agents in multiple sclerosis. Can J Neurol Sci 1999; 26: 274-5
16. MS-Therapie Konsensus Gruppe. Immunmodulatorische Stufentherapie der multiplen Sklerose, 1: Ergänzung. Dezember 2000. Nervenarzt 2001; 72: 150-7
17. European Study Group on Interferon Beta-1B IN Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-7
18. Goodkin DE, North American Study Group on Interferon Beta-1B in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial [abstract]. Neurology 2000; 54: 2352
19. Spectrims Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-504
20. Li DK, Zhao GJ, Paty DW, et al. Randomized controlled trial of intefferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001; 56: 1505-13
21. Cohen JA, Goodman AD, Heidenreich FR, et al. Results of IMPACT, a phase 3 trial of interferon beta-1a in secondary progressive multiple sclerosis [abstractl. Neurology 2001; 56 Suppl.: A148-9
22. Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS. Neurology 2001; 57: 1969-75
23. Prisms Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS 4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001; 56: 1628-36
24. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-85
25. Brex PA, Jenkins R, Fox NC, et al: Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000; 54: 1689-91
26. Jeffery DR. Early intervention with immunomodulatory agents in the treatment of multiple sclerosis. J Neurol Sci 2002; 197: 1-8
27. Jacobs LD, Beck R, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904
28. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-82
29. Coyle PK, Hartung HP. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Mult Scler 2002; 8: 2-9
30. National Multiple Sclerosis Society USA (NMSS). Disease management consensus statement [online]. Available from URL:http://www.nmss.org [Accessed 2003 Jun 13]
31. Johnson K, Brooks BR, Ford C, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000; 6: 255-66
32. Blumhardt L, Wood C. The economics of multiple sclerosis, a cost of illness study. Br J Med Econ 1996; 10: 99-118
33. Murphy N, Confavreux C, Haas J, et al. Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 1998; 13: 607-22
34. Holmes J, Madgwick T, Bates D. The cost of multiple sclerosis. Br J Med Econ 1995; 8: 181-93
35. Upmeier H, Miltenburger C. The cost of multiple sclerosis in Germany: a top down analysis [abstract]. 16th Annual Meeting of the ISTAHC; 2000 Jun 18-21; The Hague
36. Parkin D, McNamee P, Jacoby A, et al. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assess 1998; 2: iii-54
37. Pope GC, Urato CJ, Kulas ED, et al. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations. Neurology 2002; 58: 37-43
38. Miltenburger C, Kobelt G. Quality of life and cost of multiple sclerosis. Clin Neurol Neurosurg 2002; 104: 272-5
39. Henriksson F, Fredrikson S, Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 2001; 8: 27-35
40. Kobelt G, Lindgren P, Smala A, et al. Cost and quality of life in multiple sclerosis: an observational study in Germany. Health Econ Prevent Care 2001; 2: 60-8
41. Kobelt G, Lindgren P, Parkin D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional observational study in the United Kingdom. Stockholm: EFI Research Reports, 2000
42. Amato MP, Battaglia MA, Caputo D, et al: The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002; 249: 152-63
43. Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000; 6: 91-8
44. Jönsson B. Economic evaluation of health care technologies. Acta Endocrinol 1993; 128: 50-4
45. Johannesson M. Theory and methods for economic evaluation of health care. Boston (MA): Kluwer Academic Publishers, 1996
46. Forbes RB, Lees A, Waugh N, et al. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ 1999; 319: 1529-33
47. Henriksson F, Jönsson B. The economic evaluation and consequences of multiple sclerosis. Int Mult Scler J 2000; 7: 9-17
48. Kobelt G, Jonsson L, Henriksson F, et al. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care 2000; 16: 768-80
49. Kobelt G, Jonsson L, Miltenburger C, et al. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis using natural history disease data. Int J Technol Assess Health Care 2002; 18: 127-38
50. Kobelt G, Jönsson L, Fredrikson S. Cost-utility of interferon β-1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. Eur J Health Econ. In press
51. Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health 2002; 5: 44-54
52. Coyle PK, Vollmer T, Lepen C, et al. Long-term cost-effectiveness of interferon beta-1a (Rebif 44μg tiw) in the treatment of relapsing-remitting multiple sclerosis: an econometric model [abstract]. J Neurol 2002; 249 Suppl. 1: 201-2